MedTrace Logo

Real-life Assessment of Abilify Maintena + Rexult in Schizophrenia

NCT05169268 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 6

Last updated 2026-04-27

No results posted yet for this study

Summary

MainRexult study aims to carefully evaluate a cohort of patients with schizophrenia and related disorder prescribed with the combination therapy with Abilify Maintena and Rexulti on its efficacy and tolerability in a real-life clinical setting.

Conditions

  • Schizophrenia and Related Disorders
  • Anxiety Depression

Interventions

DRUG

ARIPiprazole Injection [Abilify]

subject already receiving the combination of Abilify Maintena and Rexulti

DRUG

Brexpiprazole

subject already receiving the combination of Abilify Maintena and Rexulti

Sponsors & Collaborators

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Albert KK Chung · The University of Hong Kong

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-01
Primary Completion
2026-01-31
Completion
2026-01-31
FDA Drug
Yes

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05169268 on ClinicalTrials.gov